Annual General Meeting in Photocure ASA

Published: 29 April 2010Medical congresses & eventsFinancial Investment & Stock

Oslo, Norway, April 29, 2010.

The Annual General Meeting in Photocure ASA took place on April 28, 2010.

Please find attached minutes from the meeting.

For further information, please contact:

President and CEO Kjetil Hestdal


Mobile: +47 913 19 535

CFO Christian Fekete


Mobile: +47 916 42 938

About Photocure

Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.


Photocure's commercial activities includes own marketing and sales in selected markets as well as out-licensing on a regional or global basis prior to phase III.


Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved in EU. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM)platform.


For more information about Photocure, visit our website at


Photocure®, the Photocure logo and Hexvix® are registered trademarks of Photocure ASA.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events